Key statistics
Previous close$98.71
Open$100.00
Day high$100.46
Day low$95.84
52-week high$132.03
52-week low$84.70
Market cap11.65B
Volume1.89M
Average volume2.94M
P/E ratio14.27
Forward P/E12.45
EPS6.75
Dividend yield+5.15%
Market context
Why it moved
Clorox shares declined after management sharply lowered its full-year earnings guidance, citing ERP transition costs, inventory normalization, and GOJO integration dilution as drivers of organic sales declines, overshadowing an otherwise better-than-expected quarterly earnings beat.
What is happening
Recent company-specific developments and publisher coverage.
July 18, 2026Clorox shares fell over 2% amid a broadly risk-off session, underperforming the consumer staples sector (XLP) as JP Morgan cut its price target to $92 while maintaining an Underweight rating. The stock faces persistent analyst headwinds — Goldman Sachs holds a Sell with an $83 target, Barclays rates it Underweight at $85, and the consensus sits at a cautious 'Reduce' — even as some institutional investors have been accumulating shares and the company's Q1 beat ($1.64 EPS vs. $1.55 estimate) provided fundamental support.-2.4212
July 17, 2026Clorox closed modestly higher, outpacing the broader Consumer Staples sector (XLP +2.6%) as defensive positioning drove the strongest staples session since April 2025. The gain came despite fresh analyst headwinds: JPMorgan cut its price target on CLX from $95 to $92 while maintaining an Underweight rating, though UBS offered a partial offset by raising its target from $96 to $100 with a Neutral rating. Morningstar named Clorox a top Q3 pick among undervalued consumer defensive stocks, and the stock continues to trade above its 52-week low of $84.70 following better-than-expected Q3 EPS of $1.64 vs. $1.55 consensus.1.8154
July 16, 2026Clorox shares rose sharply, outperforming the consumer defensive sector (XLP) and the broader S&P 500, after the company beat earnings expectations and maintained stable revenue — renewing investor interest in the stock as a defensive play. The move was further supported by a favorable macro backdrop, with a softer-than-expected June CPI report easing Fed rate hike concerns and lifting consumer staples broadly. Morningstar also named Clorox a top Q3 pick in the consumer defensive sector, noting it appears undervalued, while the stock continues to trade well below its 200-day moving average amid a cautious analyst consensus.2.3219
July 15, 2026Clorox closed slightly lower as investors weigh a complex backdrop ahead of its August 3 fiscal Q4 earnings report. Analyst sentiment remains cautious — the consensus sits at 'Reduce' with an average price target of $103.40 — with multiple firms having cut targets following management's lowered FY2026 guidance, which now calls for net sales to decline roughly 6% and gross margin contraction of 250–300 basis points due to persistent manufacturing, logistics, and tariff cost pressures. Notably, Morningstar named Clorox a top Q3 consumer defensive pick, citing undervaluation, while a DCF analysis pegs intrinsic value near $165/share — well above current levels — though margin recovery remains the key catalyst investors are waiting on.-0.3156
July 14, 2026Clorox declined amid a broad market selloff driven by renewed U.S.-Iran tensions, which sent oil prices surging over 4% and rattled investor sentiment heading into earnings season. The consumer staples sector (XLP) also closed lower, offering little refuge, as investors assessed Clorox's own challenging backdrop — a lowered fiscal 2026 outlook calling for ~6% sales decline and gross margin contraction — ahead of its August 3 fourth-quarter earnings webcast. On a positive note, Morningstar named Clorox a top Q3 pick among undervalued consumer defensive stocks, and Bank of America reiterated a Hold with a $102 target, while analysts see a consensus fair value near $105.-1.5638
July 11, 2026Clorox shares rallied sharply, outperforming the broader consumer staples sector (XLP edged up modestly) and the S&P 500, as investors rotated into defensive, dividend-paying consumer staples names amid ongoing U.S.-Iran military tensions in the Gulf that have rattled broader market sentiment. The bounce comes after CLX slipped 2.4% the prior session and follows a period of sustained weakness — shares are down roughly 26% over the past year — with Wall Street maintaining a cautious consensus 'Reduce' rating and an average price target of ~$103. Despite recent institutional buying (including new positions from Y Intercept Hong Kong and O Domhnaill Enterprises) and insider purchases by a director at ~$85.82/share in May, analysts have broadly cut price targets following Q3 earnings that showed flat revenue growth and margin pressure from elevated energy costs.3.7499
July 9, 2026Clorox shares fell sharply, underperforming the broader consumer staples sector (XLP closed lower) as a confluence of headwinds weighed on the stock. Goldman Sachs cut its price target on CLX to $77 from $83 — the most bearish target on the Street — reinforcing a cautious consensus of 'Reduce' among analysts even as the company beat Q3 EPS estimates ($1.64 vs. $1.55 expected). The broader market selloff, triggered by Trump declaring the U.S.-Iran ceasefire 'over' and sending oil prices surging 5%+, hit risk assets broadly; however, CLX declined more sharply than defensive peers, suggesting company-specific pressure from the Goldman target cut compounded macro headwinds. Shares recovered modestly in after-hours trading.-3.5931
July 8, 2026Clorox closed essentially flat, holding steady near the $97 level as defensive consumer staples faced headwinds from a broad risk-on rotation that favored semiconductors and technology over staples names. The Consumer Staples ETF (XLP) pulled back on the day as chips led gains and investors rotated away from defensive sectors. Against that backdrop, Clorox continues to trade well below its 52-week high of $132.03 and its 200-day moving average of $104.24, weighed down by cautious analyst sentiment — the stock carries a consensus "Reduce" rating with an average price target of $103.40 — and a wave of post-earnings target cuts from major firms including JPMorgan, Barclays, and Citigroup following its April 30 results.0.1645
www.marketscreener.com · July 16, 2026UBS Adjusts Price Target on Clorox to $100 From $96, Maintains Neutral Rating↗Moomoo · July 16, 2026J.P. Morgan Maintains Clorox(CLX.US) With Sell Rating, Cuts Target Price to $92↗TradingView · July 14, 2026Is Household Segment Strength Enough to Sustain Clorox's Growth?↗Seeking Alpha · July 9, 2026Clorox: Quality Isn't In Question, But Valuation Is↗PR Newswire · June 17, 2026Clorox Announces Simplified Operating Structure to Improve Execution and Accelerate Growth↗Pluang · May 11, 2026Clorox faces investor lawsuit over alleged misl...↗Investing.com · April 30, 2026Earnings call transcript: Clorox Q3 2026 beats EPS estimates amid mixed results↗U.S. Consumer Product Safety Commission (.gov) · January 27, 2026Clorox Agrees to Pay $14.15 Million Civil Penalty for Failure to Immediately Report Bacterial Hazard with Pine-Sol Scented Multi-Surface Cleaning Products↗ Benzinga · July 16, 2026JP Morgan Maintains Underweight on Clorox, Lowers Price Target to $92Benzinga · July 16, 2026UBS Maintains Neutral on Clorox, Raises Price Target to $100Mt Newswire · July 16, 2026JPMorgan Adjusts Price Target on Clorox to $92 From $95, Maintains Underweight RatingMt Newswire · July 8, 2026Goldman Sachs Adjusts Price Target on Clorox to $77 From $83Mt Newswire · June 17, 2026Clorox Names Hyder COO, Streamlines Operating StructureBenzinga · June 17, 2026Clorox Appoints Chris Hyder As COO Effective ImmediatelyMt Newswire · May 28, 2026Clorox to Start CEO Search ProcessBenzinga · May 18, 2026Wells Fargo Maintains Equal-Weight on Clorox, Lowers Price Target to $95
